Maintenance therapy has generally been shown to improve outcomes in newly diagnosed multiple myeloma (NDMM). [1] [2] [3] [4] [5] [6] [7] [8] Increases in progression-free survival (PFS) and overall survival (OS) have been demonstrated in some trials of maintenance therapy, 4-6 but others have reported improved PFS with no corresponding improvement in OS. [1] [2] [3] The lack of OS benefit may be due to crossover and insufficient follow-up, as well as the fact that these trials
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Maintenance therapy has generally been shown to improve outcomes in newly diagnosed multiple myeloma (NDMM). [1] [2] [3] [4] [5] [6] [7] [8] Increases in progression-free survival (PFS) and overall survival (OS) have been demonstrated in some trials of maintenance therapy, [4] [5] [6] but others have reported improved PFS with no corresponding improvement in OS. [1] [2] [3] The lack of OS benefit may be due to crossover and insufficient follow-up, as well as the fact that these trials
were not powered to detect differences in OS between treatment groups. Theoretically, an experimental treatment may negatively affect OS (despite improving PFS) by increasing long-term toxicity or altering the tumor population or microenvironment to induce drug resistance or evolution of an aggressive clone. [9] [10] [11] To account for these possibilities, the European Medicines Agency (EMA) has recently recommended using "progression-free survival 2" (PFS2) as a clinical end-point to evaluate the efficacy of maintenance therapy in hematology/oncology trials. 10 To rule out possible negative effects of treatment on the efficacy of next-line therapy, PFS2 in the experimental arm should be sufficiently superior to that in the control arm. 10 In this article, we explore the concept of PFS2 and apply it to a trial in NDMM patients to determine whether lenalidomide maintenance therapy influenced the efficacy of subsequent treatment. For this analysis, as per the EMA definition, PFS2 was calculated in the intent-to-treat population as the time from randomization to the date of disease progression or death from any cause after second-line therapy. 10 Because the date of disease progression after second-line therapy was not collected prospectively, the starting date of third-line therapy was used as a proxy to PFS2, as recommended by the EMA. 10 Comparisons between treatment groups were made using a proportional hazards model. P-values were based on an unstratified log-rank test of Kaplan-Meier curves between treatment groups. The data cutoff for this analysis was April 30, 2013, and the median follow-up was 62 months.
Of the 152 patients assigned to MPR-R (data cut off April 30, 2013), 85 started second-line therapy, 5 died before second-line therapy was initiated, and 62 had no disease progression. (Table 1) . Adverse cytogenetic features were slightly more common in the MPR-R and MPR groups (32% and 35%, respectively) than in the MP group (26%).
Patients originally assigned to MPR-R were more likely to receive a bortezomib-based regimen as second-line therapy (49%) than those originally assigned to MP (21%), whereas lenalidomide-based therapy was more commonly chosen for patients originally assigned to MP (72%) or MPR (58%) than for those who received MPR-R (28%) ( Table 2 ).
Median PFS2 was 39.7 months in the MPR-R group, 27.8 months in the MPR group, and 28.8 months in the MP group (Figure 1 ). MPR-R was associated with a significant (30%) 
P=0.505).
The present results confirm that adding lenalidomide therapy to MP provided a clinically meaningful progression-free interval that was nearly 1 year longer than that achieved with MP, even when accounting for second-line therapy and the different types of subsequent regimens used. Furthermore, the fact that PFS2 was significantly longer with MPR-R than MP despite the high number of patients in the MP arm who received lenalidomide as second-line therapy (72%) supports the incorporation of lenalidomide in the first-line setting, rather than waiting until relapse. Median PFS2 in the MPR group was similar to that in the MP group, which indirectly suggests an important contribution of maintenance therapy.
Although there was a trend toward improved PFS2 with MPR-R (39. It is important to note that PFS2 differs from "2nd PFS", which is the PFS associated with For optimal results, PFS2 should be included as a pre-specified clinical trial end-point, and the use of next-line therapy should be specified in the protocol to ensure uniform care in relapsing patients. This study was designed several years before the EMA defined PFS2, and we could explore this concept only in a retrospective analysis. A similar post hoc approach has been used in other trials of maintenance therapy in transplant-ineligible NDMM patients. 12, 13 Palumbo et al. 13 pooled data from two phase III trials comparing continuous therapy with fixed-duration therapy and found that median PFS2 was significantly 
